[An antiemetic guideline for patients with malignancies in Japan].
Recent developments in chemotherapeutic regimens have improved overall and progression-free survival in patients with various malignancies. Supportive care accompanied by antiemetic treatment is crucial for successful chemotherapy. Hence, high-level evidence with regard to antiemetic therapy is essential to create awareness among oncologists. This study reviewed evidence from clinical trials involving antiemetic therapy in Japanese patients with malignancies, and established an antiemetic guideline for oncologists in Japan. Here, we introduce the outline of this antiemetic guideline.
Takeuchi
Hideki
H
Department of Breast Oncology, International Medical Center, Saitama Medical University.
Saeki
Toshiaki
T
D000932:Antiemetics / Q000592:standards* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017408:Guidelines as Topic; D006801:Humans; D007564:Japan; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D009369:Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
D000932:Antiemetics; D000970:Antineoplastic Agents